PT  - JOURNAL ARTICLE
AU  - Naushin, Salwa
AU  - Sardana, Viren
AU  - Ujjainiya, Rajat
AU  - Bhatheja, Nitin
AU  - Kutum, Rintu
AU  - Bhaskar, Akash Kumar
AU  - Pradhan, Shalini
AU  - Prakash, Satyartha
AU  - Khan, Raju
AU  - Rawat, Birendra Singh
AU  - Tallapaka, Karthik Bharadwaj
AU  - Anumalla, Mahesh
AU  - Chandak, Giriraj Ratan
AU  - Lahiri, Amit
AU  - Kar, Susanta
AU  - Mulay, Shrikant Ramesh
AU  - Mugale, Madhav Nilakanth
AU  - Srivastava, Mrigank
AU  - Khan, Shaziya
AU  - Srivastava, Anjali
AU  - Tomar, Bhawna
AU  - Veerapandian, Murugan
AU  - Venkatachalam, Ganesh
AU  - Vijayakumar, Selvamani Raja
AU  - Agarwal, Ajay
AU  - Gupta, Dinesh
AU  - Halami, Prakash M
AU  - Peddha, Muthukumar Serva
AU  - Sundaram, Gopinath M
AU  - Veeranna, Ravindra P
AU  - Pal, Anirban
AU  - Agarwal, Vinay Kumar
AU  - Maurya, Anil Ku
AU  - Singh, Ran Vijay Kumar
AU  - Raman, Ashok Kumar
AU  - Anandasadagopan, Suresh Kumar
AU  - Karuppanan, Parimala
AU  - Venkatesan, Subramanian
AU  - Sardana, Harish Kumar
AU  - Kothari, Anamika
AU  - Jain, Rishabh
AU  - Thakur, Anupma
AU  - Parihar, Devendra Singh
AU  - Saifi, Anas
AU  - Kaur, Jasleen
AU  - Kumar, Virendra
AU  - Mishra, Avinash
AU  - Goger, Iranna
AU  - Rayasam, Geethavani
AU  - Singh, Praveen
AU  - Chakraborty, Rahul
AU  - Chaturvedi, Gaura
AU  - Karunakar, Pinreddy
AU  - Yadav, Rohit
AU  - Singhmar, Sunanda
AU  - Singh, Dayanidhi
AU  - Sarkar, Sharmistha
AU  - Bhattacharya, Purbasha
AU  - Acharya, Sundaram
AU  - Singh, Vandana
AU  - Verma, Shweta
AU  - Soni, Drishti
AU  - Seth, Surabhi
AU  - Vashisht, Shakshi
AU  - Thakran, Sarita
AU  - Fatima, Firdaus
AU  - Singh, Akash Pratap
AU  - Sharma, Akanksha
AU  - Sharma, Babita
AU  - Subramanian, Manikandan
AU  - Padwad, Yogendra
AU  - Hallan, Vipin
AU  - Patial, Vikram
AU  - Singh, Damanpreet
AU  - Tirpude, Narendra Vijay
AU  - Chakrabarti, Partha
AU  - Maity, Sujay Krishna
AU  - Ganguly, Dipyaman
AU  - Sarkar, Jit
AU  - Ramakrishna, Sistla
AU  - Kumar, Balthu Narender
AU  - Kumar, A Kiran
AU  - Gandhi, Sumit G.
AU  - Jamwal, Piyush Singh
AU  - Chouhan, Rekha
AU  - Jamwal, Vijay Lakshmi
AU  - Kapoor, Nitika
AU  - Ghosh, Debashish
AU  - Thakkar, Ghanshyam
AU  - Subudhi, Umakanta
AU  - Sen, Pradip
AU  - Chaudhury, Saumya Ray
AU  - Kumar, Rashmi
AU  - Gupta, Pawan
AU  - Tuli, Amit
AU  - Sharma, Deepak
AU  - Ringe, Rajesh P.
AU  - D, Amarnarayan
AU  - Kulkarni, Mahesh
AU  - Shanmugam, Dhanasekaran
AU  - Dharne, Mahesh S
AU  - Dastager, Syed G.
AU  - Joshi, Rakesh
AU  - Patil, Amita P.
AU  - Mahajan, Sachin N.
AU  - Khan, Abu Junaid
AU  - Wagh, Vasudev
AU  - Yadav, Rakeshkumar
AU  - Khilari, Ajinkya
AU  - Bhadange, Mayuri
AU  - Chaurasiya, Arvindkumar H.
AU  - Kulsange, Shabda E
AU  - Khairnar, Krishna
AU  - Paranjape, Shilpa
AU  - Kalita, Jatin
AU  - Sastry, G. Narahari
AU  - Phukan, Tridip
AU  - Manna, Prasenjit
AU  - Romi, Wahengbam
AU  - Bharali, Pankaj
AU  - Ozah, Dibyajyoti
AU  - Sahu, Ravi Kumar
AU  - Babu, Elapavalooru V.S.S.K.
AU  - Sukumaran, Rajeev
AU  - Nair, Aiswarya R
AU  - Kooloth-Valappil, Prajeesh
AU  - Puthiyamadam, Anoop
AU  - Velayudhanpillai, Adarsh
AU  - Chodankar, Kalpana
AU  - Damare, Samir
AU  - Madhavi, Yennapu
AU  - Aggarwal, Ved Varun
AU  - Dahiya, Sumit
AU  - Agrawal, Anurag
AU  - Dash, Debasis
AU  - Sengupta, Shantanu
TI  - Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV-2
AID  - 10.1101/2021.01.12.21249713
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.12.21249713
4099  - http://medrxiv.org/content/early/2021/02/28/2021.01.12.21249713.short
4100  - http://medrxiv.org/content/early/2021/02/28/2021.01.12.21249713.full
AB  - To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India), conducted a sero-survey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS CoV2 anti-nucleocapsid (anti-NC) antibodies; 95% with surrogate neutralization activity. Three-fourth recalled no symptoms. Repeat serology tests at 3 (n=346) and 6 (n=35) months confirmed stability of antibody response and neutralization potential. Local sero-positivity was higher in densely populated cities and was inversely correlated with a 30 day change in regional test positivity rates (TPR). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of sero-positivity were high-exposure work (Odds Ratio, 95% CI, p value; 2·23, 1·92–2·59, 6·5E-26), use of public transport (1·79, 1·43–2·24, 2·8E-06), not smoking (1·52, 1·16–1·99, 0·02), non-vegetarian diet (1·67, 1·41–1·99, 3·0E-08), and B blood group (1·36,1·15-1·61, 0·001).Impact Statement Widespread asymptomatic and undetected SARS-CoV2 infection affected more than a 100 million Indians by September 2020. Declining new cases thereafter may be due to persisting humoral immunity amongst sub-communities with high exposure.Funding Council of Scientific and Industrial Research, India (CSIR)Competing Interest StatementThe authors have declared no competing interest.Funding StatementCouncil of Scientific and Industrial Research, India (CSIR) The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CSIR IGIB: Institutional Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified categorized data of the participants can be provided on request basis after approval of ethics committee of the institute/organisation to which the requesting person belongs, stating the potential need and usage and signing of an agreement with the corresponding authors on behalf of CSIR IGIB. The request could be made to the corresponding authors after 90 days of publication.